JAMES M MARKERT, MD
Medical Practice at 19 St, Birmingham, AL

6764675, Jul 20, 2004

Feb 14, 2002

10/009972

Richard J. Whitley - Birmingham AL
James MacDowell Markert - Birmingham AL
George Yancey Gillespie - Birmingham AL
Jacqueline Ness Parker - Brimingham AL

The UAB Research Foundation - Birmingham AL

A01N 6300

424 932, 514 44, 4353201, 435455, 435456

An anti-cancer pharmaceutical composition includes a herpes simplex virus (HSV) vector into which a nucleic acid sequence encoding an anti-cancer agent selected from interleukin-12, GM-CSF, and CD has been inserted. A method of treatment of a patient suffering from cancer includes administering to the patient the anti-tumor pharmaceutical composition including an HSV vector having a nucleic acid sequence encoding an anti-cancer agent selected from interleukin-12, GM-CSF, and CD inserted therein.

2008009, Apr 24, 2008

Nov 1, 2005

11/718439

Jacqueline Parker - Birmingham AL, US
Richard Whitley - Birmingham AL, US
James Markert - Birmingham AL, US

A61K 39/245, C12N 7/01, A61P 35/00

424093200, 435235100

A conditionally replicating, aneurovirulent recombinant herpes simplex virus is provided that includes a nucleic acid encoding an expressible chemokine. An expression control element is operably linked to the nucleic acid. A therapeutic composition includes a first conditionally replicating, aneurovirulent recombinant herpes simplex virus having a first nucleic acid encoding a first expressible cytokine operatively linked to an expression control element. A second such herpes simplex virus encoding a second expressible cytokine is also provided with a pharmaceutically acceptable carrier. Preferably, the second cytokine is a chemokine. In a particular embodiment, the first expressible cytokine increases availability of an immunoresponsive cell for activation. The activatable cell is CD4+, CD8+, NK, a dendritic cell, or a combination thereof. A second conditionally replicating, aneurovirulent, recombinant herpes simplex virus expresses a second cytokine in the same host cell as the first virus or alternatively, upon expression in a second host cell, resulting in the activation of the immunoresponsive cell. A method of tumor cell growth inhibition is provided that includes introduction of a therapeutically effective amount of an aforementioned therapeutic composition into a tumor of an individual such that two different cytokines are produced within the tumor to enhance the immune response in the individual that inhibits tumor cell growth. The first and second recombinant herpes simplex viruses are administered simultaneously, sequentially. Sequential administration is separated by a time period ranging from a few second to several days.

2007022, Sep 27, 2007

Apr 27, 2007

11/796574

Donald Buchsbaum - Alabaster AL, US
G. Gillespie - Birmingham AL, US
James Markert - Birmingham AL, US
Sergey Kaliberov - Birmingham AL, US

A61K 31/70, C12N 15/869

514044000, 435320100

The instant invention has developed viral vectors encoding a mutant bacterial cytosine deaminase (bCD) gene, which have a higher affinity for cytosine than wild type bCD (bCDwt). The purpose of the present invention was to evaluate cytotoxicity in vitro and therapeutic efficacy in vivo of these vectors in combination with the prodrug 5-FC and ionizing radiation against human glioma. The present study demonstrates that infection with the viral vector expressing the mutant cytosine deaminase gene resulted in increased 5-FC-mediated cell killing, compared with vectors expressing the wild-type gene. Furthermore, a significant increase in cytotoxicity following infection with viral vector expressing the mutant cytosine deaminase gene and radiation treatment of glioma cells in vitro was demonstrated as compared to infection with viral vector expressing the wild-type gene. Animal studies showed significant inhibition of subcutaneous or intracranial tumor growth of D54MG glioma xenografts by the combination of AdbCD-D314A/5-FC with ionizing radiation as compared with either agent alone, and with AdbCDwt/5-FC plus radiation. These data indicate that combined treatment with this mutant enzyme/prodrug therapy and radiotherapy provides a promising approach for cancer therapy.

2008020, Aug 28, 2008

Jun 30, 2006

11/994158

Kevin Cassady - Birmingham AL, US
James Markert - Birmingham AL, US

THE UAB RESEARCH FOUNDATION - Birmingham AL

A61K 35/76, C12N 7/01, C12N 15/00, A61P 35/04, C12N 5/02

424 932, 4352351, 435375, 4353201, 435440

Disclosed herein are chimeric herpesviruses as well as methods of making and using such chimeric herpesviruses. The chimeric viruses comprise two nucleic acid sequences, one from a herpesvirus and one from a different virus. The herpesvirus nucleic acid sequence is a modified protein kinase R (PKR) evasion gene. The second viral nucleic acid sequence inhibits PKR-mediate protein shutoff in tumor cells, but is not neurovirulent. Thus, the chimeric virus has reduced neurovirulence as compared to the wild-type herpesvirus but remains replication competent.

2004025, Dec 23, 2004

Jul 8, 2004

10/886907

Richard Whitley - Birmingham AL, US
James Markert - Birmingham AL, US
George Gillespie - Birmingham AL, US
Jacqueline Parker - Birmingham AL, US

A61K048/00

424/093200

An anti-cancer pharmaceutical composition includes a herpes simplex virus (HSV) vector into which a nucleic acid sequence encoding for an anti-cancer agent selected from interleukin-12, GM-CSF, and CD has been inserted. A method of treatment of a patient suffering from cancer includes administering to the patient the anti-tumor pharmaceutical composition including a HSV vector having a nucleic acid sequence encoding for an anti-cancer agent selected from interleukin-12, GM-CSF, and CD inserted therein.

8420071, Apr 16, 2013

Sep 19, 2008

12/234246

Richard J. Whitley - Birmingham AL, US
James MacDowell Markert - Birmingham AL, US
George Yancey Gillespie - Birmingham AL, US
Jacqueline Nuss Parker - Birmingham AL, US

The UAB Research Foundation - Birmingham AL

A01N 63/00, A61K 48/00

424 932, 514 44 R, 4353201

An anti-cancer pharmaceutical composition includes a herpes simplex virus (HSV) vector into which a nucleic acid sequence encoding for an anti-cancer agent selected from interleukin-12, GM-CSF, and CD has been inserted. A method of treatment of a patient suffering from cancer includes administering to the patient the anti-tumor pharmaceutical composition including a HSV vector having a nucleic acid sequence encoding for an anti-cancer agent selected from interleukin-12, GM-CSF, and CD inserted therein.